ArticleActa neurologica Belgica2025
Perampanel as first line monotherapy for seizure in japan. A single-centre real-world study.
Article in Acta neurologica Belgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of this study was to examine the efficacy of Perampanel (PER) monotherapy for patients with seizures in a single-centre in Japan. The National Health Insurance began covering PER monotherapy in Japan since January 2020, after which we began using PER as monotherapy for patients with epilepsy at our institute.
methodsAll patients given PER between January 2020 and December 2022 were evaluated in this retrospective study. Treatment outcomes (including the seizure rate and seizure- free status) and patient sex, seizure type, and seizure aetiology were evaluated.
resultsSixty-three patients (29 females, 34 males) receiving PER monotherapy as the first-line antiseizure medication for epilepsy were evaluated. The age range was 12 to 88 years, with a mean age of 64.5 ± 18.8years. The follow-up period ranged from 194 days to 1004days, with a median of 576 days from PER initiation. A total of 49 patients (77.8%) were seizure free, while the other 14 patients had incomplete seizure control, including 2 patients (3.2%) who had a 75-99% reduction in seizures, 4 patients (6.3%) who had a 50-74% reduction in seizures,8 patients (12.7%) who had a 25-49% reduction in seizures, and no patients with a 0-24% reduction in seizures. The median PER dose was 2 mg (range; 2-8 mg). No patients discontinued PER monotherapy owing to adverse effects such as transient dizziness at initial administration.
conclusionPerampanel monotherapy was effective for treating a wide spectrum of seizures, especially seizures related to lesions such as brain tumours, stroke and trauma. Seizure control could be achieved with a minimum dose of PER (2 mg/day).
Indexed as
Identifiers
40820198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.